Pharmacokinetic Study of Perioperative Intravenous Ifosfamide
Table 2
Clinical features and prospective morbidity-mortality assessment of 16 patients with peritoneal surface malignancy having cytoreductive surgery and perioperative hyperthermic chemotherapy.
Patient
Gender/age
Diagnosis
Grade II morbidity
Grade III morbidity
Grade IV morbidity
Mortality
Current status (months)
1
M/47
Appendix
0
0
0
0
DOD (9)
2
F/56
Papillary serous
0
0
0
0
AWD (26)
3
F/44
Papillary serous
0
0
Hyponatremia, return to SICU
0
NED (31)
4
F/55
Papillary serous
0
0
0
0
NED (29)
5
M/19
Recurrent colon
Postoperative bleeding
0
0
0
AWD (19)
6
M/54
DMPM
Central line infection
0
0
0
AWD (20)
7
F/30
DMPM
Urinary tract infection
0
Excessive ascites, return to SICU
0
AWD (18)
8
F/61
Endometrial
Urinary tract infection
0
0
0
DOD (6)
9
F/60
DMPM
Pleural effusion
0
0
0
AWD (18)
10
F/51
DMPM
0
0
0
0
NED (16)
11
M/54
DMPM
Neuropraxia
0
0
0
NED (14)
12
M/47
Colon
0
0
0
0
AWD (14)
13
M/61
DMPM
0
0
0
0
AWD (14)
14
M/64
Gastric
0
0
0
0
DOD (6)
15
M/52
DMPM
0
0
0
0
NED (13)
16
M/58
DMPM
0
0
0
0
AWD (12)
DMPM: diffuse malignant peritoneal mesothelioma; DOD: died of disease; AWD: alive with disease; NED: no evidence of disease; SICU: surgical intensive care unit.
